Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5
- PMID: 2010630
- DOI: 10.1093/infdis/163.4.769
Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5
Abstract
To investigate whether immunization with Escherichia coli J5 boiled cells induces antibodies directed at deep core structures, antibodies against J5 lipopolysaccharide (LPS), Re LPS, and lipid A were measured in the serum of 70 volunteers before and 2 weeks after immunization. To improve the sensitivity and the specificity of ELISA, complexes of core LPS with high-density lipoproteins were used instead of free core LPS as antigens. A median three-fold increase in antibodies directed against J5 LPS was observed, but no significant increase in the antibodies against Re LPS or lipid A was found. Since J5 antiserum did not react with several smooth LPS or with Re LPS and lipid A, cross-reactivity could not be demonstrated. Thus, immunization of volunteers with E. coli J5 produced a modest specific antibody response against J5 LPS. The mechanism of protection previously observed with J5 antiserum remains unclear.
Similar articles
-
Immunochemical specificity of human antibodies to lipopolysaccharide from the J5 rough mutant of Escherichia coli O111:B4.J Infect Dis. 1989 Jan;159(1):35-42. doi: 10.1093/infdis/159.1.35. J Infect Dis. 1989. PMID: 2462603
-
Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides.J Infect Dis. 1991 Apr;163(4):762-8. doi: 10.1093/infdis/163.4.762. J Infect Dis. 1991. PMID: 1707084
-
Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram-negative bacteria and extracted lipopolysaccharides.J Infect Dis. 1989 Nov;160(5):846-57. doi: 10.1093/infdis/160.5.846. J Infect Dis. 1989. PMID: 2681436
-
Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.Vaccine. 2004 Feb 17;22(7):812-7. doi: 10.1016/j.vaccine.2003.11.025. Vaccine. 2004. PMID: 15040932 Review.
-
Antiserum treatment of gram-negative bacteremia.Schweiz Med Wochenschr. 1978 Dec 2;108(48):1872-6. Schweiz Med Wochenschr. 1978. PMID: 362528 Review.
Cited by
-
Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.Clin Exp Immunol. 1994 Jul;97 Suppl 1(Suppl 1):69-72. Clin Exp Immunol. 1994. PMID: 8033438 Free PMC article. Review.
-
Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.Infect Immun. 2000 Mar;68(3):1529-34. doi: 10.1128/IAI.68.3.1529-1534.2000. Infect Immun. 2000. PMID: 10678970 Free PMC article. Clinical Trial.
-
Milk and serum J5-specific antibody responses, milk production change, and clinical effects following intramammary Escherichia coli challenge for J5 vaccinate and control cows.Clin Vaccine Immunol. 2007 Jun;14(6):693-9. doi: 10.1128/CVI.00104-07. Epub 2007 Apr 25. Clin Vaccine Immunol. 2007. PMID: 17460115 Free PMC article.
-
Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.Infect Immun. 2001 Mar;69(3):1351-7. doi: 10.1128/IAI.69.3.1351-1357.2001. Infect Immun. 2001. PMID: 11179298 Free PMC article. Clinical Trial.
-
Monoclonal antibodies in sepsis and septic shock.BMJ. 1992 Jan 18;304(6820):132-3. doi: 10.1136/bmj.304.6820.132. BMJ. 1992. PMID: 1571053 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical